<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01906866</url>
  </required_header>
  <id_info>
    <org_study_id>NEU_CH_7911</org_study_id>
    <nct_id>NCT01906866</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities</brief_title>
  <official_title>A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurim Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurim Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the efficacy and safety of Circadin in children
      with neurodevelopmental disorders and to determine the dose, this randomized,
      placebo-controlled study is planned to evaluate the efficacy of a double-blind, 13 week
      treatment period with Circadin 2/5mg in improving maintenance of sleep, sleep latency and
      additional parameters in children with neurodevelopmental disabilities. The efficacy and
      safety of Circadin 2/5 mg will continue to be assessed during an open-label extension period
      of 13 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">March 27, 2018</completion_date>
  <primary_completion_date type="Actual">March 27, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Total Sleep Time Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary Questionnaire After the 13 Week, Double-blind Treatment Period.</measure>
    <time_frame>13 weeks</time_frame>
    <description>Total Sleep Time - To compare the treatment effect of Circadin® 2/5 mg minitablets to that of placebo on total sleep time (TST) as assessed by the Sleep and Nap Diary after 13 weeks of double-blind treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep Latency Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary After 13 Weeks of Double-blind Treatment.</measure>
    <time_frame>13 weeks</time_frame>
    <description>questionnaire - To compare the treatment effect of Circadin® 2/5 mg minitablets to that of placebo on sleep latency as derived from a Sleep and Nap Diary after 13 weeks of double-blind treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Duration of Wake After Sleep Onset Period Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary After 13 Weeks of Double-blind Treatment.</measure>
    <time_frame>up to 1.5 years</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Awakenings During the Night Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary After 13 Weeks of Double-blind Treatment.</measure>
    <time_frame>up to 1.5 years</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Duration of the Longest Sleep Period Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary After 13 Weeks of Double-blind Treatment.</measure>
    <time_frame>up to 1.5 Years</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Children's Social Functioning at Home, in School, and Community Settings Will be Measured for the Circadin 2/5 mg and Placebo by the Children Global Assessment Scale (CGAS) Questionnaire After 13 Weeks of Double-blind Treatment.</measure>
    <time_frame>up to 1.5 years</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Children's Behavior at Home, in School, and Community Will be Measured for the Circadin 2/5 mg and Placebo by the Strength of Difficulties Questionnaire (SDQ) Questionnaire Filled Out by the Parents After 13 Weeks of Double-blind Treatment.</measure>
    <time_frame>up to 1.5 years</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Dropouts Between Circadin 2/5 mg to That of Placebo Will be Compared During the 13 Weeks of Double-blind Treatment.</measure>
    <time_frame>up to 1.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Parameters (Rest/Activity Cycles) Will be Measured for the Circadin 2/5 mg and Placebo as Measured by Actigraphy After 13 Weeks of Double-blind Treatment.</measure>
    <time_frame>up to 1.5 years</time_frame>
    <description>The Actigraph will be worn on the wrist at night and collect the Sleep parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability Throughout the Study Will be Measured for the Circadin 2/5 mg and Placebo Throughout the Study Using AE Eliciting Method Treatment Emergent Signs and Symptoms (TESS)</measure>
    <time_frame>up to 2.5 years</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Following Vital Signs Will be Measured: Blood Pressure, Pulse, Breathing and Body Temperature. They Will be Compared Between the Circadin and Placebo Groups.</measure>
    <time_frame>up to 2.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Sleep Disorders</condition>
  <arm_group>
    <arm_group_label>Circadin 2/5/10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Circadin 2/5/10 mg</intervention_name>
    <description>Active arm</description>
    <arm_group_label>Circadin 2/5/10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be eligible for study entry, all patients must satisfy all of the following criteria at
        screening:

          1. Must be children 2 to 17.5 years of age at Visit 2 who comply with taking the study
             drug

          2. Must have written informed consent provided by a legal guardian and assent (if needed)

          3. Must have a documented history of ASD according to or consistent with the ICD-10 or
             DSM-5/4 criteria, or neurodevelopmental disabilities caused by neurogenetic diseases
             (i.e., Smith-Magenis syndrome, Angelman syndrome, Bourneville's disease [tuberous
             sclerosis]) as confirmed by case note review showing that diagnosis was reached
             through assessment by a community pediatrician or pediatric neurologist or other
             health care professionals experienced in the diagnosis who took into account early
             developmental history and school records.

          4. Must have current sleep problems including: a minimum of 3 months of impaired sleep
             defined as ≤6 hours of continuous sleep AND/OR ≥0.5 hour sleep latency from light off
             in 3 out of 5 nights based on parent reports and patient medical history. (The
             maintenance and latency problems do not necessarily have to be in the same 3 nights of
             the week.)

          5. May be on a stable dose of non-excluded medication for 3 months, including anti-
             epileptics, anti-depressants (selective serotonin reuptake inhibitor [SSRIs]),
             stimulants, all mood changing drugs and β-blockers. (Only morning administration of
             β-blockers is allowed since β-blockers at night have the potential to reduce
             endogenous melatonin levels and might cause disturbed sleep)

          6. The sleep disturbance is not due to the direct physiological effects of any
             concomitant medications such as SSRIs, stimulants, etc.

        After completing 4 weeks of sleep hygiene training (for those who need it) and 2 weeks of
        placebo run-in, patients will be eligible to continue the study if they comply with the
        following:

          -  Continue to fulfill sleep problem criteria (see Inclusion Criterion 4) based on the
             completed Sleep and Nap Diary entered into the electronic case report form

          -  Parents demonstrate compliance in Sleep and Nap Diary completion (5 out of 7 nights).
             Compliance means that in at least 5 out of 7 nights per week (total of 2 weeks before
             each scheduled visit) the parents complete the diary pages with all mandatory
             questions

          -  Continue to fulfil all other eligibility criteria

        Exclusion Criteria:

        Children who meet any of the following criteria will be excluded from participating in the
        study:

          1. Have had treatment with any form of melatonin within 2 weeks prior to Visit 1

          2. Have a known allergy to melatonin or lactose

          3. Have a known moderate to severe sleep apnea

          4. Have an untreated medical/ineffectively treated/psychological condition that may be
             the etiology of sleep disturbances

          5. Did not respond to previous Circadin® therapy based on past medical history records in
             the last 2 years

          6. Are taking or have been taking prohibited medication within 2 weeks prior to Visit 1
             (Section 7.1)

          7. Are females of child-bearing potential that are not using contraceptives and/or
             breastfeeding and that are sexually active (Abstinence is an acceptable method of
             contraception.)

          8. Pregnant females

          9. Are currently participating in a clinical trial or have participated in a clinical
             trial involving medicinal product within the last 3 months prior to the study (this
             does not include patients who participated in the Phase I PK study who can be already
             included in the study)

         10. Children with known renal or hepatic insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Gringras, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thoma`s Hospital, Westminster Bridge Rd, London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Findling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kennedy Krieger Institute, Baltimore, Maryland, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southwest Autism Research and Resource Center (SARRC)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crystal BioMedical Research, LLC</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake Mary Pediatrics</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mate Lazlo</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Attalla Consultants LLC, dba Institue for Behabiovral medicine</name>
      <address>
        <city>Smyrna</city>
        <state>Georgia</state>
        <zip>30080-6315</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMR Baber research INC</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kennedy Krieger Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Child Neurology Specialists/ CRCN</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical research center of New Jersey, LLC</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geinsinger Clinic</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The children`s hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INSITE Clinical Research</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Red Oak Psychiatry Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Therapy &amp; Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Road Runner Research, Ltd</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ericksen Research &amp; Development</name>
      <address>
        <city>Clinton</city>
        <state>Utah</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific institute of medical science</name>
      <address>
        <city>Bothell</city>
        <state>Washington</state>
        <zip>98011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki Sleep Clinic Vitalmed OY</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Raymond Poincare</name>
      <address>
        <city>Garches</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strasbourg University Hospital Depatment of Child Psychiatry &amp; Neurology</name>
      <address>
        <city>Strasbourg,</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yulius Mental Health Organization</name>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gelderse Vallei</name>
      <address>
        <city>Ede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Childrens Hospital NHS FOUNDATION TRUST</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blackpool Victoria Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's &amp; St. Thomas's NHS Foundation Trust of St Thomas's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>July 11, 2013</study_first_submitted>
  <study_first_submitted_qc>July 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2013</study_first_posted>
  <results_first_submitted>October 2, 2018</results_first_submitted>
  <results_first_submitted_qc>October 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2018</results_first_posted>
  <last_update_submitted>May 7, 2019</last_update_submitted>
  <last_update_submitted_qc>May 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sleep disturbance</keyword>
  <keyword>Circadian</keyword>
  <keyword>Prolong release melatonin</keyword>
  <keyword>Autism Spectrum Disorder</keyword>
  <keyword>Smith-Magenis Syndrome</keyword>
  <keyword>Angelman Syndrome</keyword>
  <keyword>tuberous sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Dyssomnias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 19, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT01906866/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 10, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT01906866/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Circadin 2/5/10 mg</title>
          <description>Circadin 2/5/10 mg: Active arm</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo arm
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients in the Safety Analysis Set who satisfied all major entry criteria (Criteria 1-5) and who had a valid mean TST result recorded for baseline and at least one post-baseline period assessment during the double blind phase. Patients were classified according to randomized treatment. This analysis set was used for all efficacy analysis</population>
      <group_list>
        <group group_id="B1">
          <title>Circadin 2/5/10 mg</title>
          <description>Circadin 2/5/10 mg: Active arm</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo arm
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="65"/>
            <count group_id="B3" value="125"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="125"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9" spread="4.08"/>
                    <measurement group_id="B2" value="8.4" spread="4.24"/>
                    <measurement group_id="B3" value="8.7" spread="4.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Total Sleep Time Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary Questionnaire After the 13 Week, Double-blind Treatment Period.</title>
        <description>Total Sleep Time - To compare the treatment effect of Circadin® 2/5 mg minitablets to that of placebo on total sleep time (TST) as assessed by the Sleep and Nap Diary after 13 weeks of double-blind treatment</description>
        <time_frame>13 weeks</time_frame>
        <population>All patients in the Safety Analysis Set who satisfied all major entry criteria (I.Criteria 1-5) and who had a valid mean TST result recorded for baseline and at least one post-baseline period assessment during the double blind phase. Patients were classified according to randomized treatment. This analysis set was used for all efficacy analyses</population>
        <group_list>
          <group group_id="O1">
            <title>Circadin 2/5/10 mg</title>
            <description>Circadin 2/5/10 mg: Active arm Units: minutes arithmetic mean (standard error): 51.03 (±10.46)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo arm Units: minutes arithmetic mean (standard error): 18.71 (±10.82)</description>
          </group>
        </group_list>
        <measure>
          <title>The Total Sleep Time Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary Questionnaire After the 13 Week, Double-blind Treatment Period.</title>
          <description>Total Sleep Time - To compare the treatment effect of Circadin® 2/5 mg minitablets to that of placebo on total sleep time (TST) as assessed by the Sleep and Nap Diary after 13 weeks of double-blind treatment</description>
          <population>All patients in the Safety Analysis Set who satisfied all major entry criteria (I.Criteria 1-5) and who had a valid mean TST result recorded for baseline and at least one post-baseline period assessment during the double blind phase. Patients were classified according to randomized treatment. This analysis set was used for all efficacy analyses</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.03" lower_limit="30.3" upper_limit="71.76"/>
                    <measurement group_id="O2" value="18.71" lower_limit="-2.73" upper_limit="40.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.035</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>32.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>15.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.38</ci_lower_limit>
            <ci_upper_limit>62.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Latency Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary After 13 Weeks of Double-blind Treatment.</title>
        <description>questionnaire - To compare the treatment effect of Circadin® 2/5 mg minitablets to that of placebo on sleep latency as derived from a Sleep and Nap Diary after 13 weeks of double-blind treatment</description>
        <time_frame>13 weeks</time_frame>
        <population>All patients in the Safety Analysis Set who satisfied all major entry criteria (I.Criteria 1-5) and who had a valid mean TST result recorded for baseline and at least one post-baseline period assessment during the double blind phase. Patients were classified according to randomized treatment. This analysis set was used for all efficacy analyses</population>
        <group_list>
          <group group_id="O1">
            <title>Circadin 2/5/10 mg</title>
            <description>Circadin 2/5/10 mg: Active arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo arm
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Latency Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary After 13 Weeks of Double-blind Treatment.</title>
          <description>questionnaire - To compare the treatment effect of Circadin® 2/5 mg minitablets to that of placebo on sleep latency as derived from a Sleep and Nap Diary after 13 weeks of double-blind treatment</description>
          <population>All patients in the Safety Analysis Set who satisfied all major entry criteria (I.Criteria 1-5) and who had a valid mean TST result recorded for baseline and at least one post-baseline period assessment during the double blind phase. Patients were classified according to randomized treatment. This analysis set was used for all efficacy analyses</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.77" spread="6.816"/>
                    <measurement group_id="O2" value="-12.57" spread="7.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.011</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-25.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.787</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.61</ci_lower_limit>
            <ci_upper_limit>-5.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Duration of Wake After Sleep Onset Period Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary After 13 Weeks of Double-blind Treatment.</title>
        <description>Questionnaire</description>
        <time_frame>up to 1.5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Awakenings During the Night Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary After 13 Weeks of Double-blind Treatment.</title>
        <description>Questionnaire</description>
        <time_frame>up to 1.5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Duration of the Longest Sleep Period Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary After 13 Weeks of Double-blind Treatment.</title>
        <description>Questionnaire</description>
        <time_frame>up to 1.5 Years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Children's Social Functioning at Home, in School, and Community Settings Will be Measured for the Circadin 2/5 mg and Placebo by the Children Global Assessment Scale (CGAS) Questionnaire After 13 Weeks of Double-blind Treatment.</title>
        <description>Questionnaire</description>
        <time_frame>up to 1.5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Children's Behavior at Home, in School, and Community Will be Measured for the Circadin 2/5 mg and Placebo by the Strength of Difficulties Questionnaire (SDQ) Questionnaire Filled Out by the Parents After 13 Weeks of Double-blind Treatment.</title>
        <description>Questionnaire</description>
        <time_frame>up to 1.5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Dropouts Between Circadin 2/5 mg to That of Placebo Will be Compared During the 13 Weeks of Double-blind Treatment.</title>
        <time_frame>up to 1.5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Parameters (Rest/Activity Cycles) Will be Measured for the Circadin 2/5 mg and Placebo as Measured by Actigraphy After 13 Weeks of Double-blind Treatment.</title>
        <description>The Actigraph will be worn on the wrist at night and collect the Sleep parameters</description>
        <time_frame>up to 1.5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability Throughout the Study Will be Measured for the Circadin 2/5 mg and Placebo Throughout the Study Using AE Eliciting Method Treatment Emergent Signs and Symptoms (TESS)</title>
        <description>Questionnaire</description>
        <time_frame>up to 2.5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Following Vital Signs Will be Measured: Blood Pressure, Pulse, Breathing and Body Temperature. They Will be Compared Between the Circadin and Placebo Groups.</title>
        <time_frame>up to 2.5 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>104 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Circadin 2/5/10 mg Double Blind</title>
          <description>Circadin 2/5/10 mg: Active arm</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo arm
Placebo</description>
        </group>
        <group group_id="E3">
          <title>Circadin 2/5/10 mg Open Label</title>
          <description>Circadin 2/5/10 mg Open label</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>SAE -Serious adverse event</sub_title>
                <description>CONSTIPATION</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>SAE - Serious adverse event</sub_title>
                <description>PNEUMONIA EYE INFECTION OTITIS MEDIA ACUTE</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>SAE -Serious adverse event</sub_title>
                <description>AGGRESSION OPPOSITIONAL DEFIANT DISORDER Abnormal behaviour</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Non-serious adverse events</sub_title>
                <description>VOMITING DIARRHOEA NAUSEA CONSTIPATION</description>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="60"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="65"/>
                <counts group_id="E3" events="58" subjects_affected="40" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-serious adverse events</sub_title>
                <description>FATIGUE PYREXIA HANGOVER</description>
                <counts group_id="E1" events="28" subjects_affected="23" subjects_at_risk="60"/>
                <counts group_id="E2" events="28" subjects_affected="19" subjects_at_risk="65"/>
                <counts group_id="E3" events="49" subjects_affected="39" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Non-serious adverse events</sub_title>
                <description>UPPER RESPIRATORY TRACT INFECTION INFLUENZA OTITIS MEDIA GASTROENTERITIS NASOPHARYNGITIS SINUSITIS</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="60"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E3" events="61" subjects_affected="46" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Non-serious adverse events</sub_title>
                <description>SOMNOLENCE HEADACHE</description>
                <counts group_id="E1" events="26" subjects_affected="25" subjects_at_risk="60"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="65"/>
                <counts group_id="E3" events="51" subjects_affected="42" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Non-serious adverse events</sub_title>
                <description>MOOD SWINGS AGITATION ANXIETY AGGRESSION</description>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="60"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="65"/>
                <counts group_id="E3" events="47" subjects_affected="36" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Non-serious adverse events</sub_title>
                <description>COUGH DYSPNOEA ASTHMA RHINORRHOEA</description>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="60"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="65"/>
                <counts group_id="E3" events="50" subjects_affected="37" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Non-serious adverse events</sub_title>
                <description>Rash</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Tali Nir</name_or_title>
      <organization>Neurim Pharmaceuticals</organization>
      <phone>972-7684902</phone>
      <email>talin@neurim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

